BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21800344)

  • 21. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma.
    Buckley AF; Burgart LJ; Kakar S
    Hum Pathol; 2006 Apr; 37(4):410-4. PubMed ID: 16564914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor beta actions in hepatocytes--but without modulating bone morphogenetic protein 7 signaling.
    Gressner OA; Lahme B; Siluschek M; Rehbein K; Weiskirchen R; Gressner AM
    Hepatology; 2009 Jun; 49(6):2021-30. PubMed ID: 19309720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy.
    Perugorria MJ; Castillo J; Latasa MU; Goñi S; Segura V; Sangro B; Prieto J; Avila MA; Berasain C
    Cancer Res; 2009 Feb; 69(4):1358-67. PubMed ID: 19190340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
    Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
    Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
    Sugano Y; Matsuzaki K; Tahashi Y; Furukawa F; Mori S; Yamagata H; Yoshida K; Matsushita M; Nishizawa M; Fujisawa J; Inoue K
    Oncogene; 2003 Apr; 22(15):2309-21. PubMed ID: 12700666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5.
    Zhang B; Shan H; Li D; Li ZR; Zhu KS; Jiang ZB; Huang MS
    Oncol Rep; 2011 Feb; 25(2):461-8. PubMed ID: 21152876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma.
    Shiraki K; Yamanaka T; Inoue H; Kawakita T; Enokimura N; Okano H; Sugimoto K; Murata K; Nakano T
    Int J Oncol; 2005 May; 26(5):1273-81. PubMed ID: 15809718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin.
    Shin EC; Seong YR; Kim CH; Kim H; Ahn YS; Kim K; Kim SJ; Hong SS; Park JH
    Exp Mol Med; 2002 May; 34(2):114-22. PubMed ID: 12085986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
    Liu ZM; Tseng JT; Hong DY; Huang HS
    Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells.
    Yang JF; Cao JG; Tian L; Liu F
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):195-206. PubMed ID: 21660448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
    Gu Z; Lee RY; Skaar TC; Bouker KB; Welch JN; Lu J; Liu A; Zhu Y; Davis N; Leonessa F; Brünner N; Wang Y; Clarke R
    Cancer Res; 2002 Jun; 62(12):3428-37. PubMed ID: 12067985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
    Fuchs BC; Fujii T; Dorfman JD; Goodwin JM; Zhu AX; Lanuti M; Tanabe KK
    Cancer Res; 2008 Apr; 68(7):2391-9. PubMed ID: 18381447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumoural Expression of Connective Tissue Growth Factor (CTGF) Impacts on Survival in Patients Diagnosed with Hepatocellular Carcinoma (HCC).
    Lamarca A; Mendiola M; Bernal E; Heredia V; Díaz E; Miguel M; Pastrian LG; Burgos E; Feliu J; Barriuso J
    Curr Cancer Drug Targets; 2015; 15(5):435-44. PubMed ID: 25847009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relationship between death receptor 5 and apoptosis in hepatocellular carcinoma].
    Zhu RX; Lin JS; Song YH; Li PY; Tao LW
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):261-4. PubMed ID: 16875623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of paraxanthine as the most potent caffeine-derived inhibitor of connective tissue growth factor expression in liver parenchymal cells.
    Gressner OA; Lahme B; Siluschek M; Gressner AM
    Liver Int; 2009 Jul; 29(6):886-97. PubMed ID: 19291178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The epidermal growth factor receptor: a link between inflammation and liver cancer.
    Berasain C; Perugorria MJ; Latasa MU; Castillo J; Goñi S; Santamaría M; Prieto J; Avila MA
    Exp Biol Med (Maywood); 2009 Jul; 234(7):713-25. PubMed ID: 19429859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The tyrphostin AG1478 inhibits proliferation and induces death of liver tumor cells through EGF receptor-dependent and independent mechanisms.
    Caja L; Sancho P; Bertran E; Ortiz C; Campbell JS; Fausto N; Fabregat I
    Biochem Pharmacol; 2011 Dec; 82(11):1583-92. PubMed ID: 21864510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties.
    Liu AM; Poon RT; Luk JM
    Biochem Biophys Res Commun; 2010 Apr; 394(3):623-7. PubMed ID: 20226166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of serum connective tissue growth factor in patients with hepatocellular carcinoma and relationship with angiogenesis.
    Wang GB; Zhou XY; Yuan T; Xie J; Guo LP; Gao N; Wang XQ
    World J Surg; 2010 Oct; 34(10):2411-7. PubMed ID: 20512490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.